1. Home
  2. WEN vs ABCL Comparison

WEN vs ABCL Comparison

Compare WEN & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wendy's Company (The)

WEN

Wendy's Company (The)

HOLD

Current Price

$7.35

Market Cap

1.5B

ML Signal

HOLD

Logo AbCellera Biologics Inc.

ABCL

AbCellera Biologics Inc.

HOLD

Current Price

$5.68

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WEN
ABCL
Founded
1969
2012
Country
United States
Canada
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.6B
IPO Year
2000
2020

Fundamental Metrics

Financial Performance
Metric
WEN
ABCL
Price
$7.35
$5.68
Analyst Decision
Hold
Strong Buy
Analyst Count
22
5
Target Price
$8.84
$8.40
AVG Volume (30 Days)
9.9M
5.2M
Earning Date
05-08-2026
05-11-2026
Dividend Yield
8.28%
N/A
EPS Growth
N/A
10.91
EPS
0.12
N/A
Revenue
$2,176,891,000.00
$75,128,000.00
Revenue This Year
$2.26
N/A
Revenue Next Year
$0.94
$21.85
P/E Ratio
$61.13
N/A
Revenue Growth
N/A
160.56
52 Week Low
$6.07
$2.75
52 Week High
$10.84
$8.44

Technical Indicators

Market Signals
Indicator
WEN
ABCL
Relative Strength Index (RSI) 47.80 43.22
Support Level $6.79 $5.17
Resistance Level $8.26 $5.63
Average True Range (ATR) 0.31 0.43
MACD -0.04 -0.13
Stochastic Oscillator 35.55 30.26

Price Performance

Historical Comparison
WEN
ABCL

About WEN Wendy's Company (The)

The Wendy's Co is engaged in operating, developing, and franchising a system of distinctive quick-service restaurants serving high-quality food. The company operates through Wendy's U.S., Wendy's International, and Global Real Estate & Development. Wendy's U.S. and Wendy's International include the operation and franchising of restaurants and derive revenues from sales at company-operated restaurants, as well as royalties, franchise fees, and advertising fund collections from franchised restaurants. Global Real Estate & Development includes real estate activities for owned and leased sites that are leased or subleased to franchisees and includes the company's share of income from its Canadian restaurant real estate joint venture.

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.

Share on Social Networks: